Clinical trials: Central Line
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS)
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
This study is open to adults with specific types of advanced soft tissue sarcoma. People with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) can join the study if they have a normal version of the TP53 gene.
- Conditions
- Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
- Trial name
- NCT06370871
- Testing
- Brigimadlin, Ezabenlimab, Gemcitabine
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether gemcitabine plus CI-994 is more effective than gemcitabine alone for non-small…
- Trial name
- NCT00005093
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Dysfunctional Central Venous Access Catheters
A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters
This was a Phase III, open-label, single-arm study that was conducted at 43 centers in the United States and Canada. 251 adult and pediatric patients with dysfunctional central venous catheters (CVCs) were enrolled in the study…
- Trial name
- TROPICS 2 (NCT00396318)
- Testing
- tenecteplase
- Volunteers
- 251 people
- Sponsor
- Genentech, Inc.
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer NSCLC
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients…
- Trial name
- ORION (NCT03775486)
- Testing
- Durvalumab, Olaparib, Nab-paclitaxel+carboplatin
- Where
- 68 sites in United States, Belgium and 10 more
- Volunteers
- 401 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received…
- Trial name
- CEVOLUTION (NCT07555938)
- Testing
- Cevostamab, Pomalidomide, Dexamethasone
- Where
- 93 sites in United States, Australia and 16 more
- Volunteers
- 380 people
- Sponsor
- Hoffmann-La Roche
Glabellar Frown Lines
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in…
- Trial name
- EV-006 (NCT02428608)
- Testing
- DWP-450 (Botulinum purified neurotoxin, Type A)
- Where
- United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Surgical Procedures, Operative
A Study Comparing ETHICON™ 4000 Stapler System With Standard of Care Stapling Devices in Adults Undergoing Gastric and Thoracic Procedures
The purpose of this study is to compare how well the ETHICON™ 4000 Stapler works as compared to the standard stapling devices by assessing how often air leaks and bleeding along the staple line occur during lung and stomach…
- Trial name
- NCT07744568
- Testing
- ETHICON™ 4000 Stapler System, Standard of Care Stapler and Reloads
- Volunteers
- 300 people
- Sponsor
- Ethicon Endo-Surgery
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer
The purpose of the study is to assess the efficacy and safety and PK of AZD8931 plus paclitaxel versus paclitaxel alone in patients with metastatic, gastric or gastro-oesophageal junction, cancer.
- Trial name
- NCT01579578
- Testing
- AZD8931, Paclitaxel
- Where
- 15 sites in Germany, Japan and 3 more
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Thrombosis
Pediatric Catheter-related Thrombosis Imaging Study
This protocol will serve as a pilot study to determine the validity and feasibility of contrast enhanced magnetic resonance imaging (MRI) without and with contrast and/or ultrasound (US) for detection of catheter related deep…
- Trial name
- AESOP (NCT01137578)
- Testing
- Ultrasound, Magnetic Resonance Imaging with Contrast, Magnetic Resonance Imaging without Contrast
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 151 people
- Sponsor
- Bristol-Myers Squibb
Keloid
Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids
This trial will explore the efficacy and safety of 250ng Juvista per Linear cm, administered by intradermal injection following the excision of ear lobe keloids.
- Trial name
- NCT00836147
- Testing
- Avotermin (Juvista)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Renovo
Central Line Associated Blood Stream Infections (CLABSI)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN)…
- Trial name
- NCT06822426
- Testing
- (taurolidine and heparin) catheter lock solution, Heparin
- Where
- 24 sites in United States, Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- CorMedix Therapeutics
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
GVHD, Chronic
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
1. Phase Ib study stage: Primary objective: To evaluate the efficacy and safety Secondary objectives: To evaluate the population pharmacokinetic characteristics 2.
- Trial name
- NCT06169722
- Testing
- TDI01 suspension
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01493505
- Testing
- AMG 386, Paclitaxel, Carboplatin
- Where
- 310 sites in United States, Austria and 12 more
- Volunteers
- 1,015 people
- Sponsor
- Amgen
Advanced Colorectal Carcinoma
Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma
This is a phase 2, randomized, double-blind, multi-center clinical study to evaluate efficacy and safety of a maintenance therapy with the immunomodulator MGN1703 compared to placebo control.
- Trial name
- IMPACT (NCT01208194)
- Testing
- MGN1703
- Where
- 12 sites in Austria, Czechia and 4 more
- Volunteers
- 59 people
- Sponsor
- Mologen AG
Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced…
- Trial name
- NCT07490262
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.